Intellia Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Unaudited consolidated results. Intellia is a clinical-stage gene-editing company developing CRISPR/Cas9-based in vivo and ex vivo therapies. It reported no product-sale revenue; all revenue to date has been collaboration revenue. Dollar amounts below are in millions unless otherwise stated.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Collaboration revenue | $28.9 | $12.6 |
| Research and development expense | $111.8 | $97.1 |
| General and administrative expense | $31.1 | $27.4 |
| Operating loss | $(114.0) | $(112.0) |
| Other income, net | $6.6 | $8.8 |
| Net loss | $(107.4) | $(103.1) |
| Basic and diluted loss per share | $(1.12) | $(1.17) |
| Net cash used in operating activities | $(120.7) | $(109.3) |
- Revenue increased 129% year over year, largely because Intellia recognized $21.0 million of previously eliminated intra-entity profit related to AvenCell. This was a noncash accounting recognition, not a comparable recurring revenue source.
- Operating expenses rose 15%, including higher external development costs for NTLA-2001 and NTLA-2002, increased stock-based compensation, and a one-time charge related to a January 2024 workforce reduction. Operating loss widened slightly; net loss increased by $4.3 million. Loss per share improved as weighted-average shares rose to 95.5 million from 87.8 million.
- At March 31, cash and cash equivalents were $172.0 million and marketable securities totaled $781.4 million, for $953.4 million in cash, cash equivalents and marketable securities. Total assets were $1,259.6 million; total liabilities were $223.5 million; stockholders’ equity was $1,036.1 million. Current assets were $884.0 million and current liabilities $97.9 million.
- No borrowings or financial debt are identified in the presented balance sheet. Operating lease liabilities totaled $110.9 million; deferred revenue totaled $55.6 million. The company reported $120.7 million of operating cash outflow and raised $58.0 million net through at-the-market (ATM) stock sales in the quarter.
- Management estimates current cash, cash equivalents, marketable securities and collaboration reimbursements can fund operating expenses and capital expenditures into late 2026, excluding potential collaboration milestones or extension fees and strategic uses of capital. The filing also states resources cover at least twelve months after issuance.
Material changes and unusual items
- In February, Intellia expanded its ATM program from $400 million to $750 million. During Q1 it sold 2.21 million shares at an average $26.19 per share, receiving $56.0 million net; $371.1 million remained available under the program at quarter-end. The share count increased to 96.3 million from 93.0 million at December 31, 2023.
- Kyverna’s February IPO changed the valuation basis for Intellia’s investment: its reported value rose from $10.0 million to $29.2 million, producing a $19.2 million unrealized gain. AvenCell’s financing and governance changes ended equity-method accounting; Intellia recognized $21.0 million of previously eliminated collaboration profit and recorded a $25.3 million impairment, leaving a $9.6 million carrying value. The combined net change in fair value of investments was a $6.1 million expense.
- Intellia notified Regeneron in March that it would opt out of the hemophilia B co-development and co-funding agreement; obligations continue through September 2024, after which development obligations are governed by the broader Regeneron agreement.
- Intellia entered a ReCode collaboration in February focused on cystic fibrosis. No upfront consideration was exchanged and no Q1 revenue was recognized; potential payments include development and commercial milestones of up to $262 million per product and single-digit royalties, subject to agreement terms.
- Regeneron’s $30 million nonrefundable payment for a two-year technology-collaboration extension through April 2026 was received in April 2024, after quarter-end.
Outlook, programs and risks
- Management expects expenses to increase during the remainder of 2024 as clinical programs advance. Intellia expects to rely on collaboration funding and future financing until it can generate substantial product revenue; no committed external source of liquidity exists beyond identified collaboration arrangements.
- NTLA-2001: The company reported active enrollment in the global Phase 3 MAGNITUDE trial for ATTR cardiomyopathy, with the first U.S. and global patients dosed in March. It said enrollment was ahead of initial projections, with over 30 patients dosed and more than 40 in screening. It plans to initiate a separate Phase 3 study for ATTRv-PN by year-end, subject to an IND, and present updated Phase 1 data in the second half of 2024.
- NTLA-2002: Phase 2 enrollment and dosing were completed in January. Intellia expects topline Phase 2 results in mid-2024 and plans to initiate a global pivotal Phase 3 study in the second half of 2024, subject to regulatory feedback. The FDA had requested supplemental preclinical data relating to female patients of child-bearing potential; timing and outcome remain uncertain.
- NTLA-3001: Intellia expects to dose the first patient in a Phase 1 study in 2024. These are company expectations, not guarantees; the filing emphasizes that clinical results, timelines and regulatory outcomes are uncertain.
- Key risks include the unproven safety and efficacy of in vivo genome editing, potential unintended edits or serious adverse events, clinical-trial delays or failures, manufacturing and supply constraints, regulatory uncertainty, dependence on collaborators, and the need for additional capital. Patent disputes concerning CRISPR/Cas9 rights remain a material risk; an appeal involving the UC/Vienna/Charpentier and Broad Institute patent families had oral argument on May 7, 2024. The company reported no material change in litigation since year-end 2023.
- Contingent license payments tied to development, regulatory and commercial milestones are uncertain and not reasonably estimable. The filing identifies no material change in contractual obligations during the quarter. Disclosure controls were deemed effective as of March 31, 2024.
Investor verification checklist
- Check whether the $21.0 million AvenCell revenue recognition and $25.3 million impairment are correctly understood as unusual, nonrecurring accounting effects, and review the investment’s valuation assumptions.
- Track actual clinical enrollment, data releases and regulatory progress for NTLA-2001, NTLA-2002 and NTLA-3001 against management’s stated timelines.
- Monitor operating cash use against the late-2026 runway estimate, including future clinical and facility spending, collaboration reimbursements and any financing needs.
- Assess dilution from the expanded ATM program, remaining authorized sales and equity compensation awards.
- Follow the CRISPR patent proceedings and any resulting effects on Intellia’s licensed rights, collaborations or development programs.
- Confirm receipt and accounting treatment of Regeneron’s $30 million extension payment, and review the transition and remaining obligations under the hemophilia B agreement.